Barinthus Biotherapeutics plc (BRNS)
USD 0.7
(-0.6%)
USD 0.7
(-0.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -50.92 Million | -14.43 Million | -32.58 Million | -11.02 Million | -18.75 Million |
| Net Income | -73.44 Million | 5.32 Million | -51.11 Million | -17.93 Million | -20.81 Million |
| Depreciation & Amortization | 5.42 Million | 4.32 Million | 602 Thousand | 208 Thousand | 346.86 Thousand |
| Deferred income taxes | -3.07 Million | -4.33 Million | -119 Thousand | -2.48 Million | - |
| Stock-based compensation | 5.05 Million | 9.87 Million | 16.48 Million | 3.62 Million | - |
| Change in working capital | 6.17 Million | -5.52 Million | -7.17 Million | 1.92 Million | 2.93 Million |
| Other non-cash items | 8.94 Million | -24.09 Million | 8.73 Million | 3.63 Million | -2.55 Million |
| Investing Cash Flow | -5.41 Million | -5.75 Million | -12.91 Million | -293 Thousand | 1.92 Million |
| Investments in PPE | -5.41 Million | -6.13 Million | -1.14 Million | -293 Thousand | -128.34 Thousand |
| Acquisitions | - | 387.76 Thousand | -11.76 Million | 252.89 Thousand | 2.05 Million |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -5.41 Million | 240.00 | - | -252.89 Thousand | - |
| Financing Cash Flow | 1.87 Million | 325 Thousand | 222.74 Million | 41.43 Million | 1.00 |
| Debt repayment | - | -159 Thousand | - | -41.5 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 2.03 Million | 484 Thousand | 102.77 Million | 49.38 | 1.00 |
| Other Financing Activities | -163 Thousand | - | 119.96 Million | 82.93 Million | - |
| Accounts receivables | 5.8 Million | -5.83 Million | 559 Thousand | 479 Thousand | -963.16 Thousand |
| Accounts payables | -3.37 Million | 1.14 Million | -3.52 Million | 586 Thousand | 2.97 Million |
| Inventory | - | -648 Thousand | -4.14 Million | 889 Thousand | - |
| Other working capital | 3.74 Million | -183 Thousand | -63 Thousand | -32 Thousand | 924.57 Thousand |
| Cash at beginning of period | 194.38 Million | 214.05 Million | 43.26 Million | 11.43 Million | 28.26 Million |
| Cash at end of period | 142.09 Million | 194.38 Million | 214.05 Million | 43.26 Million | 11.43 Million |
| Capital Expenditure | -5.41 Million | -6.13 Million | -1.14 Million | -293 Thousand | -128.34 Thousand |
| Effect of forex changes on cash | 2.17 Million | 187 Thousand | -6.45 Million | 1.72 Million | -0.15 |
| Net cash flow / Change in cash | -52.29 Million | -19.66 Million | 170.78 Million | 31.83 Million | -16.83 Million |
| Free Cash Flow | -56.33 Million | -20.56 Million | -33.72 Million | -11.32 Million | -18.88 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -16.94 Million | -15.48 Million | -17.29 Million | -73.44 Million | -14.11 Million | -23.82 Million |
| Depreciation & Amortization | 1.46 Million | 1.42 Million | 1.43 Million | 5.42 Million | 1.47 Million | 1.29 Million |
| Deferred income taxes | -7034.92 | -36.97 Thousand | -821 Thousand | -3.07 Million | -602 Thousand | -1.13 Million |
| Stock-based compensation | 1.19 Million | 1.61 Million | 786 Thousand | 5.05 Million | 57 Thousand | 1.99 Million |
| Change in working capital | 1.45 Million | 1.28 Million | -10.88 Million | 6.17 Million | 8.25 Million | 542 Thousand |
| Other non-cash items | 2.77 Million | 4.7 Million | 7.16 Million | 8.94 Million | -6.26 Million | 4.17 Million |
| Investing Cash Flow | -192.33 Thousand | -307.82 Thousand | 153 Thousand | -5.41 Million | -36 Thousand | -3.02 Million |
| Investments in PPE | -192.33 Thousand | -307.82 Thousand | 153 Thousand | -5.41 Million | -36 Thousand | -3.02 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -5.41 Million | -5.41 Million | - | - |
| Financing Cash Flow | 358.55 Thousand | 502.71 Thousand | 109 Thousand | 1.87 Million | 46 Thousand | 28 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 358.55 Thousand | 502.71 Thousand | 109 Thousand | 2.03 Million | 46 Thousand | 91 Thousand |
| Other Financing Activities | - | 503 Thousand | 88.04 | -163 Thousand | 311.71 | -63 Thousand |
| Accounts receivables | 682.92 Thousand | -330.81 Thousand | -558.5 Thousand | 5.8 Million | 194 Thousand | 645 Thousand |
| Accounts payables | 1.49 Million | -523.7 Thousand | -3.79 Million | -3.37 Million | 2.33 Million | -209 Thousand |
| Inventory | - | - | 558.5 Thousand | - | -1.18 Million | -511.98 Thousand |
| Other working capital | -716.33 Thousand | 2.13 Million | -7.08 Million | 3.74 Million | 6.91 Million | 617.98 Thousand |
| Cash at beginning of period | 129.97 Million | 142.09 Million | 160.3 Million | 194.38 Million | 173.03 Million | 191.32 Million |
| Cash at end of period | 117.77 Million | 129.97 Million | 142.09 Million | 142.09 Million | 160.3 Million | 173.03 Million |
| Capital Expenditure | -192.33 Thousand | -307.82 Thousand | 153 Thousand | -5.41 Million | -36 Thousand | -3.02 Million |
| Effect of forex changes on cash | -357 Thousand | -492 Thousand | 1.12 Million | 2.17 Million | -1.54 Million | 1.65 Million |
| Net cash flow / Change in cash | -12.19 Million | -12.11 Million | -18.21 Million | -52.29 Million | -12.72 Million | -18.29 Million |
| Free Cash Flow | -12.21 Million | -12.12 Million | -19.45 Million | -56.33 Million | -11.22 Million | -19.98 Million |
FUNC
ORN
GGPXF
6668
9888
IPW